HomeAGIO • BMV
add
Agios Pharmaceuticals Inc
Previous close
$1,222.00
Year range
$397.93 - $1,222.00
Market cap
3.18B USD
Avg Volume
33.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 8.96M | 21.15% |
Operating expense | 38.54M | 49.24% |
Net income | 947.92M | 1,137.97% |
Net profit margin | 10.57K | 956.76% |
Earnings per share | -1.47 | 10.66% |
EBITDA | -101.47M | -2.21% |
Effective tax rate | 5.31% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.00B | 55.18% |
Total assets | 1.79B | 77.89% |
Total liabilities | 165.12M | 37.13% |
Total equity | 1.63B | — |
Shares outstanding | 57.03M | — |
Price to book | 42.83 | — |
Return on assets | -20.04% | — |
Return on capital | -21.31% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 947.92M | 1,137.97% |
Cash from operations | -84.22M | -36.62% |
Cash from investing | 250.79M | 537.49% |
Cash from financing | 2.64M | 40.12% |
Net change in cash | 169.21M | 928.66% |
Free cash flow | -3.03M | 95.64% |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
385
